Breast cancer (BC) remains a leading cause of death among women today, and mortality
among African American women in the US remains 40% higher than that of their White …

Clinical research in high-income countries is increasingly demonstrating the
costeffectiveness of clinical pharmacogenetic (PGx) testing in reducing the incidence of …

Somatic mutations are an inevitable component of ageing and the most important cause of
cancer. The rates and types of somatic mutation vary across individuals, but relatively few …

Immune checkpoint blockade (ICB) is a promising therapy for solid tumors, but its
effectiveness depends on biomarkers that are not precise. Here, we utilized genome-wide …

Purpose Epigenetic regulation plays critical roles in cancer progression, and high-frequency
mutations or expression variations in epigenetic regulators have been frequently observed …

Black women across the African diaspora experience more aggressive breast cancer with
higher mortality rates than white women of European ancestry. Although inter-ethnic …

Race-related variation in breast cancer incidence and mortality are well-documented in the
United States. The effect of genetic ancestry on disparities in tumor genomics, risk factors …

The article in the Journal by Kerlikowske et al.(1) evaluates outcomes of breast cancer
screening for supplemental magnetic resonance imaging (MRI) plus mammography, MRI …

High‐grade serous ovarian carcinoma (HGSC) is the most common subtype of ovarian
cancer and is among the most fatal gynecological malignancies worldwide, due to late …

Despite much vaunted progress in cancer therapeutics and diagnostics, outcomes for many
groups of non-White patients with cancer remain worse than those for their White …